ASH 2018 | MM has a bright future: highlights from ASH

VJHemOnc is committed to improving our service to you

Mark Bustoros

Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses his highlights in the field of multiple myeloma (MM) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Bustoros points to the Phase III MAIA trial (NCT02252172), which evaluated the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. Rd alone in transplant-ineligible newly diagnosed MM. Dr Busteros also discusses other trials hoping to improve the outlook for patients and reshape the therapeutic landscape.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter